Mangoceuticals, Inc.
Nasdaq · Healthcare · Services-Misc Health & Allied Services, Nec · Dallas, TX
MGRX chart
What traders are saying about $MGRX
Latest postsMangoceuticals, Inc. news
- Mangoceuticals, Inc. Estimates – NASDAQ:MGRX
TradingView ·
- Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close
Yahoo Finance ·
- Mangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology Assets
Yahoo Finance ·
- Mangoceuticals’ Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development
Yahoo Finance ·
- Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination
Yahoo Finance ·
- Nuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor
Yahoo Finance ·
- Mangoceuticals Announces Business Combination Agreement with Nuclea Energy Inc. to Advance Next-Generation Nuclear Microreactor Technology
Yahoo Finance ·
- Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.
Yahoo Finance ·
- Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds
Yahoo Finance ·
- Mangoceuticals’ Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study
Yahoo Finance ·
- MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program
Yahoo Finance ·
- Top Midday Decliners
Yahoo Finance ·
Mangoceuticals, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $456,021 | $615,873 | $731,493 | $8,939 |
| Net income | -$20.6M | -$8.7M | -$9.2M | -$2.0M |
| Diluted EPS | $-2.17 | $-4.80 | $-8.58 | $-0.19 |
| Total assets (year end) | $16.1M | $15.4M | $1.1M | $1.0M |
| Cash and equivalents (year end) | $1.5M | $58,653 | $739,006 | $682,860 |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Mangoceuticals, Inc.
- Ticker
- MGRX (Nasdaq)
- Industry
- Services-Misc Health & Allied Services, Nec
- Headquarters
- Dallas, TX
- Incorporated in
- TX
- Fiscal year end
- December 31
- SEC CIK
- 1938046
- Former names
- MANGOCEUTICALS, INC.
Frequently asked questions
What exchange is Mangoceuticals, Inc. listed on?
Mangoceuticals, Inc. trades on the Nasdaq under the ticker symbol MGRX.
What industry is Mangoceuticals, Inc. in?
Mangoceuticals, Inc. is classified by the SEC under "Services-Misc Health & Allied Services, Nec", part of the Healthcare sector on StockTweeting.
Where is Mangoceuticals, Inc. headquartered?
Mangoceuticals, Inc.'s business address on file with the SEC is in Dallas, TX.
When does Mangoceuticals, Inc.'s fiscal year end?
Mangoceuticals, Inc.'s fiscal year ends on December 31.
How much revenue did Mangoceuticals, Inc. report?
Mangoceuticals, Inc. reported $456,021 in revenue for calendar year 2025, according to its SEC filings.